Takahashi Kanako, Inoue Hiroyuki, Kishimoto Masumi, Nakayama Ryuichi, Kasai Takehiko, Bunya Naofumi, Harada Keisuke, Uemura Shuji, Narimatsu Eichi
Department of Emergency Medicine, Sapporo Medical University, 16-291, Minami-1-jo Nishi, Chuo-ku, Sapporo-shi, Hokkaido 060-8543 Japan.
Division of Clinical Engineering, Sapporo Medical University Hospital, Sapporo-shi, Japan.
Ren Replace Ther. 2022;8(1):45. doi: 10.1186/s41100-022-00436-1. Epub 2022 Sep 5.
In patients with severe coronavirus disease (COVID-19), the use of acrylonitrile hemofilters can reduce cytokine concentrations. However, acrylonitrile hemofilters can easily coagulate, and the effect of hemofilters on improvement in patient prognosis remains unclear. Therefore, we aimed to investigate the changes in serum cytokine concentrations, alleviation of organ damage, and improvement in patient prognosis with continuous renal replacement therapy (CRRT) using a cellulose triacetate (CTA) filter with excellent anticoagulation property in patients with severe COVID-19.
This was a retrospective, single-center study conducted by the Advanced Critical Care Center in Sapporo Medical University Hospital, Japan. Seven patients with severe COVID-19 between March 01 and June 30, 2020, were included. The patients were under mechanical ventilation and received continuous blood purification therapy with a CTA filter. We summarized the CRRT status and patient prognosis and measured their serum cytokine (interleukin [IL]-1, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor-, and interferon-) and serum marker levels, before and after CRRT. In addition, we evaluated the changes in their respiratory status, hemodynamics, and organ dysfunction scores. The average age of the patients was 61.5 years, and five patients were male. Extracorporeal membrane oxygenation was used in five patients. The treatment outcome included three deaths.
The median CRRT duration was 7 days. The hemofilter was replaced once a day. After CRRT, the IL-6 concentration decreased from 393 to 85 pg/mL ( = 0.016), the Krebs von den Lungen-6 concentration decreased from 554 to 350 U/mL, and the PaO/FiO ratio increased significantly from 90 to 248, and therefore, oxygenation improved. In addition, the norepinephrine dose and lactate level decreased, and the circulation tended to improve; however, the renal function and Sequential Organ Failure Assessment score did not change.
The serum IL-6 level decreased, and the respiratory status improved upon CRRT using a CTA filter in patients with severe COVID-19.
在重症冠状病毒病(COVID-19)患者中,使用丙烯腈血液滤过器可降低细胞因子浓度。然而,丙烯腈血液滤过器容易凝血,血液滤过器对改善患者预后的效果仍不清楚。因此,我们旨在研究在重症COVID-19患者中使用具有优异抗凝性能的三醋酸纤维素(CTA)滤器进行连续性肾脏替代治疗(CRRT)时血清细胞因子浓度的变化、器官损伤的减轻以及患者预后的改善情况。
这是一项由日本札幌医科大学医院高级重症监护中心进行的回顾性单中心研究。纳入了2020年3月1日至6月30日期间的7例重症COVID-19患者。这些患者接受机械通气,并使用CTA滤器进行持续血液净化治疗。我们总结了CRRT情况和患者预后,并在CRRT前后测量了他们的血清细胞因子(白细胞介素[IL]-1、IL-4、IL-6、IL-8、IL-10、肿瘤坏死因子-α和干扰素-γ)和血清标志物水平。此外,我们评估了他们呼吸状态、血流动力学和器官功能障碍评分的变化。患者的平均年龄为61.5岁,5例为男性。5例患者使用了体外膜肺氧合。治疗结果包括3例死亡。
CRRT的中位持续时间为7天。血液滤过器每天更换一次。CRRT后,IL-6浓度从393降至85 pg/mL(P = 0.016),克雷布斯冯登龙根-6浓度从554降至350 U/mL,动脉血氧分压/吸入氧分数值从90显著升至248,因此氧合改善。此外,去甲肾上腺素剂量和乳酸水平降低,循环趋于改善;然而,肾功能和序贯器官衰竭评估评分没有变化。
在重症COVID-19患者中使用CTA滤器进行CRRT时,血清IL-6水平降低,呼吸状态改善。